ProBio, a subsidiary of GenScript, is a global CDMO offering end-to-end services from discovery to GMP for plasmids, antibodies, and cell & gene therapies. We bring together multidisciplinary expertise to accelerate development and manufacturing through customized, and comprehensive services.
ProBio provides end‑to‑end CGT support, covering CMC for plasmids, viral vectors, mRNA vaccines, and nucleic acid drugs, from IND filing through clinical and commercial manufacturing. Our integrated CMC services span cell banking, process development, characterization and validation, analytical development, and stability studies.
We also offer innovative biologics discovery and development capabilities, including antibody discovery, engineering, and in vitro/in vivo pharmacology. ProBio delivers a full DNA‑to‑GMP platform with stable cell line development, host cell licensing, process and analytical development, and clinical to commercial manufacturing.
We have established GMP capacity meeting the regulatory requirements of the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and National Medical Products Administration (NMPA).
ProBio CDMO - Biologics and CGT CDMO Services.